A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

February 7, 2026

Study Completion Date

February 7, 2026

Conditions

Celiac DiseaseHealthy

Interventions

DRUG

HB-2121

HB-2121 taken once orally.

Trial Locations (1)

RECRUITING

Stanford University, Stanford

All Listed Sponsors

collaborator

Stanford's Innovative Medicines Accelerator

UNKNOWN

lead

Nielsen Fernandez-Becker

OTHER